ZIVO vs. PLX, DTIL, ALVR, GRTS, BCAB, ELUT, ATRA, TIL, PASG, and AVRO
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), AlloVir (ALVR), Gritstone bio (GRTS), BioAtla (BCAB), Elutia (ELUT), Atara Biotherapeutics (ATRA), Instil Bio (TIL), Passage Bio (PASG), and AVROBIO (AVRO). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 5.0% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Protalix BioTherapeutics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Protalix BioTherapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 784.96%. Given ZIVO Bioscience's higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than ZIVO Bioscience.
In the previous week, Protalix BioTherapeutics had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score.
ZIVO Bioscience received 94 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.
Protalix BioTherapeutics has a net margin of 11.48% compared to Protalix BioTherapeutics' net margin of -11,068.75%. ZIVO Bioscience's return on equity of 19.48% beat Protalix BioTherapeutics' return on equity.
Protalix BioTherapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.
Summary
Protalix BioTherapeutics beats ZIVO Bioscience on 13 of the 16 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
